This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ASCO '11: Roche, Avastin and Ovarian Cancer

"It's too early to reach firm conclusions about the full extent of the overall survival benefit of adding bevacizumab Avastin to the treatment regimen for newly diagnosed ovarian cancer, but it does seem very promising, particularly for patients at high risk of recurrence," said Dr. Gunnar Kristensen an investigator in the study from the Norwegian Radium Hospital in Oslo, Norway.

At a previous medical meeting, researchers reported that treatment with Avastin and chemotherapy extended the time before tumors progressed compared to chemotherapy alone -- achieving the study's primary endpoint.

Genentech intends to seek approval for Avastin in ovarian cancer later this year, pending discussions with the U.S. Food and Drug Administration over how much survival data will be necessary before the drug can be reviewed and potentially approved, said Genentech spokesperson Krysta Pellegrino.

Several other companies are presenting data on ovarian cancer drugs at this year's ASCO meeting, including Exelixis (EXEL - Get Report), Nektar Therapeutics (NKTR - Get Report) and Endocyte (ECYT - Get Report).

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ECYT $6.23 2.50%
EXEL $2.84 0.35%
NKTR $10.49 -0.66%
AAPL $132.90 0.19%
FB $81.34 -0.70%

Markets

DOW 18,110.94 +72.97 0.40%
S&P 500 2,113.05 +4.13 0.20%
NASDAQ 5,068.6130 +8.3670 0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs